Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:TCF7L2-GRK5

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: TCF7L2-GRK5
	FusionPDB ID: 89816
	FusionGDB2.0 ID: 89816
		Hgene	Tgene
	Gene symbol	TCF7L2	GRK5
	Gene ID	6934	2869
	Gene name	transcription factor 7 like 2	G protein-coupled receptor kinase 5
	Synonyms	TCF-4\|TCF4	FP2025\|GPRK5
	Cytomap	10q25.2-q25.3	10q26.11
	Type of gene	protein-coding	protein-coding
	Description	transcription factor 7-like 2HMG box transcription factor 4T-cell factor 4T-cell-specific transcription factor 4hTCF-4transcription factor 7-like 2 (T-cell specific, HMG-box)	G protein-coupled receptor kinase 5g protein-coupled receptor kinase GRK5
	Modification date	20200315	20200313
	UniProtAcc	Q9NQB0 Main function of 5'-partner protein: FUNCTION: Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2/TCF4 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine. {ECO:0000269\|PubMed:12408868, ECO:0000269\|PubMed:12727872, ECO:0000269\|PubMed:19443654, ECO:0000269\|PubMed:22699938, ECO:0000269\|PubMed:9727977}.	P34947 Main function of 5'-partner protein: FUNCTION: Serine/threonine kinase that phosphorylates preferentially the activated forms of a variety of G-protein-coupled receptors (GPCRs). Such receptor phosphorylation initiates beta-arrestin-mediated receptor desensitization, internalization, and signaling events leading to their down-regulation. Phosphorylates a variety of GPCRs, including adrenergic receptors, muscarinic acetylcholine receptors (more specifically Gi-coupled M2/M4 subtypes), dopamine receptors and opioid receptors. In addition to GPCRs, also phosphorylates various substrates: Hsc70-interacting protein/ST13, TP53/p53, HDAC5, and arrestin-1/ARRB1. Phosphorylation of ARRB1 by GRK5 inhibits G-protein independent MAPK1/MAPK3 signaling downstream of 5HT4-receptors. Phosphorylation of HDAC5, a repressor of myocyte enhancer factor 2 (MEF2) leading to nuclear export of HDAC5 and allowing MEF2-mediated transcription. Phosphorylation of TP53/p53, a crucial tumor suppressor, inhibits TP53/p53-mediated apoptosis. Phosphorylation of ST13 regulates internalization of the chemokine receptor. Phosphorylates rhodopsin (RHO) (in vitro) and a non G-protein-coupled receptor, LRP6 during Wnt signaling (in vitro). {ECO:0000269\|PubMed:19661922, ECO:0000269\|PubMed:19801552, ECO:0000269\|PubMed:20038610, ECO:0000269\|PubMed:20124405, ECO:0000269\|PubMed:21728385}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000349937, ENST00000355995, ENST00000534894, ENST00000536810, ENST00000538897, ENST00000543371, ENST00000545257, ENST00000352065, ENST00000355717, ENST00000369386, ENST00000369389, ENST00000369395, ENST00000369397, ENST00000466338, ENST00000542695,	ENST00000473264, ENST00000369108, ENST00000392870,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	16 X 11 X 11=1936	19 X 19 X 6=2166
	# samples	23	19
	** MAII score	log2(23/1936*10)=-3.07337318633022 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(19/2166*10)=-3.51096191927738 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: TCF7L2 [Title/Abstract] AND GRK5 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: TCF7L2 [Title/Abstract] AND GRK5 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	TCF7L2(114724383)-GRK5(121207635), # samples:1
Anticipated loss of major functional domain due to fusion event.	TCF7L2-GRK5 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. TCF7L2-GRK5 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. TCF7L2-GRK5 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. TCF7L2-GRK5 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	TCF7L2	GO:0000122	negative regulation of transcription by RNA polymerase II	12799378
Hgene	TCF7L2	GO:0006357	regulation of transcription by RNA polymerase II	9727977
Hgene	TCF7L2	GO:0032092	positive regulation of protein binding	12799378
Hgene	TCF7L2	GO:0032350	regulation of hormone metabolic process	15525634
Hgene	TCF7L2	GO:0042593	glucose homeostasis	15525634
Hgene	TCF7L2	GO:0043433	negative regulation of DNA-binding transcription factor activity	12799378
Hgene	TCF7L2	GO:0045444	fat cell differentiation	10937998
Hgene	TCF7L2	GO:0045892	negative regulation of transcription, DNA-templated	12799378\|15525634
Hgene	TCF7L2	GO:0045944	positive regulation of transcription by RNA polymerase II	9065401\|19168596
Hgene	TCF7L2	GO:0048625	myoblast fate commitment	10937998
Tgene	GRK5	GO:0007217	tachykinin receptor signaling pathway	17986524
Tgene	GRK5	GO:0043066	negative regulation of apoptotic process	20124405
Tgene	GRK5	GO:0046777	protein autophosphorylation	14976207

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:114724383/chr10:121207635)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across TCF7L2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across GRK5 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000534894	TCF7L2	chr10	114724383	+	ENST00000392870	GRK5	chr10	121207635	+	2016	957	177	1463	428
ENST00000534894	TCF7L2	chr10	114724383	+	ENST00000369108	GRK5	chr10	121207635	+	1515	957	177	1463	428
ENST00000536810	TCF7L2	chr10	114724383	+	ENST00000392870	GRK5	chr10	121207635	+	2016	957	177	1463	428
ENST00000536810	TCF7L2	chr10	114724383	+	ENST00000369108	GRK5	chr10	121207635	+	1515	957	177	1463	428
ENST00000545257	TCF7L2	chr10	114724383	+	ENST00000392870	GRK5	chr10	121207635	+	2016	957	177	1463	428
ENST00000545257	TCF7L2	chr10	114724383	+	ENST00000369108	GRK5	chr10	121207635	+	1515	957	177	1463	428
ENST00000355995	TCF7L2	chr10	114724383	+	ENST00000392870	GRK5	chr10	121207635	+	2016	957	177	1463	428
ENST00000355995	TCF7L2	chr10	114724383	+	ENST00000369108	GRK5	chr10	121207635	+	1515	957	177	1463	428
ENST00000543371	TCF7L2	chr10	114724383	+	ENST00000392870	GRK5	chr10	121207635	+	2016	957	177	1463	428
ENST00000543371	TCF7L2	chr10	114724383	+	ENST00000369108	GRK5	chr10	121207635	+	1515	957	177	1463	428
ENST00000538897	TCF7L2	chr10	114724383	+	ENST00000392870	GRK5	chr10	121207635	+	2016	957	177	1463	428
ENST00000538897	TCF7L2	chr10	114724383	+	ENST00000369108	GRK5	chr10	121207635	+	1515	957	177	1463	428
ENST00000349937	TCF7L2	chr10	114724383	+	ENST00000392870	GRK5	chr10	121207635	+	1814	755	38	1261	407
ENST00000349937	TCF7L2	chr10	114724383	+	ENST00000369108	GRK5	chr10	121207635	+	1313	755	38	1261	407

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000534894	ENST00000392870	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.001926399	0.9980736
ENST00000534894	ENST00000369108	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.003974041	0.9960259
ENST00000536810	ENST00000392870	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.001926399	0.9980736
ENST00000536810	ENST00000369108	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.003974041	0.9960259
ENST00000545257	ENST00000392870	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.001926399	0.9980736
ENST00000545257	ENST00000369108	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.003974041	0.9960259
ENST00000355995	ENST00000392870	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.001926399	0.9980736
ENST00000355995	ENST00000369108	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.003974041	0.9960259
ENST00000543371	ENST00000392870	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.001926399	0.9980736
ENST00000543371	ENST00000369108	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.003974041	0.9960259
ENST00000538897	ENST00000392870	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.001926399	0.9980736
ENST00000538897	ENST00000369108	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.003974041	0.9960259
ENST00000349937	ENST00000392870	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.00193092	0.9980691
ENST00000349937	ENST00000369108	TCF7L2	chr10	114724383	+	GRK5	chr10	121207635	+	0.004622051	0.9953779

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for TCF7L2-GRK5

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
TCF7L2	chr10	114724383	GRK5	chr10	121207635	755	238	YSAYKTIEHQIAVQLLTKDAKQRLGC
TCF7L2	chr10	114724383	GRK5	chr10	121207635	957	259	YSAYKTIEHQIAVQLLTKDAKQRLGC

Top

Potential FusionNeoAntigen Information of TCF7L2-GRK5 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

TCF7L2-GRK5_114724383_121207635.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:01	EHQIAVQL	0.9995	0.8003	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:06	EHQIAVQL	0.9994	0.7311	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:24	EHQIAVQL	0.9994	0.6059	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B38:02	EHQIAVQL	0.9993	0.867	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B38:01	EHQIAVQL	0.9993	0.8478	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B14:02	EHQIAVQL	0.9978	0.828	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B14:01	EHQIAVQL	0.9978	0.828	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B48:01	HQIAVQLL	0.9967	0.6588	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:10	EHQIAVQL	0.9966	0.5698	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:37	EHQIAVQL	0.9934	0.617	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:13	HQIAVQLL	0.9812	0.9127	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B13:02	HQIAVQLL	0.9697	0.7361	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B13:01	HQIAVQLL	0.9677	0.9709	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:10	HQIAVQLL	0.9525	0.6209	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:37	HQIAVQLL	0.7892	0.595	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B52:01	HQIAVQLL	0.7432	0.9474	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:01	EHQIAVQLL	0.9989	0.7844	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B38:02	EHQIAVQLL	0.9986	0.8574	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B38:01	EHQIAVQLL	0.9985	0.8392	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:24	EHQIAVQLL	0.9967	0.5488	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:06	EHQIAVQLL	0.9964	0.6677	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B13:01	IEHQIAVQL	0.9964	0.7915	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B14:01	EHQIAVQLL	0.9899	0.7303	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B14:02	EHQIAVQLL	0.9899	0.7303	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B18:01	IEHQIAVQL	0.9343	0.9033	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B44:03	IEHQIAVQL	0.9242	0.7676	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B45:01	IEHQIAVQL	0.9178	0.6818	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:10	EHQIAVQLL	0.9168	0.5134	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:37	EHQIAVQLL	0.8803	0.5398	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:13	IEHQIAVQL	0.7442	0.8469	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:37	IEHQIAVQL	0.7255	0.6437	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B13:02	HQIAVQLLT	0.7253	0.9467	8	17
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B38:02	IEHQIAVQL	0.7248	0.9154	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:18	EHQIAVQLL	0.6906	0.5949	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B50:01	IEHQIAVQL	0.4648	0.6476	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B41:01	IEHQIAVQL	0.3765	0.8109	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B52:01	IEHQIAVQL	0.2802	0.7705	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B38:01	IEHQIAVQLL	0.6688	0.8597	6	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:17	KTIEHQIAVQL	0.9995	0.9556	4	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B57:03	KTIEHQIAVQL	0.9994	0.9925	4	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B40:01	KTIEHQIAVQL	0.6463	0.5483	4	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B38:01	TIEHQIAVQLL	0.3791	0.9701	5	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:09	EHQIAVQL	0.9997	0.6716	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:12	EHQIAVQL	0.9994	0.8067	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:05	EHQIAVQL	0.9991	0.7836	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B48:03	HQIAVQLL	0.9907	0.5134	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:05	HQIAVQLL	0.974	0.9042	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B14:03	EHQIAVQL	0.8687	0.8242	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B40:06	IEHQIAVQL	0.9993	0.5498	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:09	EHQIAVQLL	0.999	0.6822	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:12	EHQIAVQLL	0.9987	0.7916	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:05	EHQIAVQLL	0.9984	0.7659	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:09	IEHQIAVQL	0.7778	0.7132	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:08	IEHQIAVQL	0.7528	0.7954	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:05	IEHQIAVQL	0.7366	0.8274	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B14:03	EHQIAVQLL	0.4247	0.7944	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B51:07	IEHQIAVQL	0.232	0.7475	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-C15:06	KTIEHQIAVQL	0.9999	0.9602	4	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B48:03	KTIEHQIAVQL	0.6035	0.6418	4	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:31	EHQIAVQL	0.9994	0.8026	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B38:05	EHQIAVQL	0.9993	0.8478	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:73	HQIAVQLL	0.9961	0.9297	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:11	EHQIAVQL	0.9934	0.7566	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:09	EHQIAVQL	0.9931	0.5793	7	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B40:12	HQIAVQLL	0.9907	0.5134	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:30	HQIAVQLL	0.9907	0.8954	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:02	HQIAVQLL	0.9902	0.9165	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B40:21	HQIAVQLL	0.9623	0.6424	8	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B40:04	IEHQIAVQL	0.9993	0.6306	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:31	EHQIAVQLL	0.999	0.7864	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B38:05	EHQIAVQLL	0.9985	0.8392	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B18:04	IEHQIAVQL	0.9588	0.9058	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B18:06	IEHQIAVQL	0.9421	0.9158	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B18:08	IEHQIAVQL	0.9412	0.9123	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B18:07	IEHQIAVQL	0.9361	0.8596	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B18:03	IEHQIAVQL	0.9347	0.8944	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B18:05	IEHQIAVQL	0.9343	0.9033	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:09	EHQIAVQLL	0.9267	0.5787	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B44:07	IEHQIAVQL	0.9242	0.7676	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B44:13	IEHQIAVQL	0.9242	0.7676	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B44:26	IEHQIAVQL	0.9242	0.7676	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:11	EHQIAVQLL	0.8555	0.6983	7	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:31	IEHQIAVQL	0.7879	0.8393	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:02	IEHQIAVQL	0.7867	0.8493	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B39:11	IEHQIAVQL	0.7431	0.7616	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B18:11	IEHQIAVQL	0.6589	0.8059	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B50:04	IEHQIAVQL	0.4648	0.6476	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B50:05	IEHQIAVQL	0.4648	0.6476	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B48:02	IEHQIAVQL	0.4371	0.7831	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B15:53	IEHQIAVQL	0.1948	0.7459	6	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B40:04	IEHQIAVQLL	0.994	0.6084	6	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B38:05	IEHQIAVQLL	0.6688	0.8597	6	16
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B41:03	TIEHQIAVQL	0.4566	0.5572	5	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B40:04	TIEHQIAVQL	0.4257	0.7659	5	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-C15:05	KTIEHQIAVQL	0.9999	0.9516	4	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-C15:02	KTIEHQIAVQL	0.9998	0.9435	4	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-A32:01	KTIEHQIAVQL	0.9961	0.9826	4	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B40:04	KTIEHQIAVQL	0.719	0.8063	4	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B40:36	KTIEHQIAVQL	0.6632	0.5248	4	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B40:49	KTIEHQIAVQL	0.6386	0.5831	4	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B40:12	KTIEHQIAVQL	0.6035	0.6418	4	15
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	HLA-B38:05	TIEHQIAVQLL	0.3791	0.9701	5	16

Top

Potential FusionNeoAntigen Information of TCF7L2-GRK5 in HLA II

TCF7L2-GRK5_114724383_121207635.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0102	YKTIEHQIAVQLLTK	3	18
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0111	YKTIEHQIAVQLLTK	3	18
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0123	YKTIEHQIAVQLLTK	3	18
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0301	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0301	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0303	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0303	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0307	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0307	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0310	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0310	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0313	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0313	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0315	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0318	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0318	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0320	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0320	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0322	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0322	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0324	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0326	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0328	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0328	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0330	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0330	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0332	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0332	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0334	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0334	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0336	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0336	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0344	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0344	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0346	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0346	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0348	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0348	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0350	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0350	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0352	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0352	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0354	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-0354	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-1107	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-1107	AVQLLTKDAKQRLGC	11	26
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-1476	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB1-1479	IAVQLLTKDAKQRLG	10	25
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB4-0101	EHQIAVQLLTKDAKQ	7	22
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB4-0101	IEHQIAVQLLTKDAK	6	21
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB4-0103	EHQIAVQLLTKDAKQ	7	22
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB4-0103	IEHQIAVQLLTKDAK	6	21
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB4-0104	EHQIAVQLLTKDAKQ	7	22
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB4-0106	EHQIAVQLLTKDAKQ	7	22
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB4-0106	IEHQIAVQLLTKDAK	6	21
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB4-0107	EHQIAVQLLTKDAKQ	7	22
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB4-0107	IEHQIAVQLLTKDAK	6	21
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB4-0108	EHQIAVQLLTKDAKQ	7	22
TCF7L2-GRK5	chr10	114724383	chr10	121207635	755	DRB4-0108	IEHQIAVQLLTKDAK	6	21

Top

Fusion breakpoint peptide structures of TCF7L2-GRK5

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
3645	IEHQIAVQLLTKDA	TCF7L2	GRK5	chr10	114724383	chr10	121207635	755

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of TCF7L2-GRK5

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	3645	IEHQIAVQLLTKDA	-7.5588	-7.6706
HLA-B14:02	3BVN	3645	IEHQIAVQLLTKDA	-4.42712	-5.47022
HLA-B52:01	3W39	3645	IEHQIAVQLLTKDA	-5.79336	-5.90516
HLA-B52:01	3W39	3645	IEHQIAVQLLTKDA	-4.82735	-5.87045
HLA-A11:01	4UQ2	3645	IEHQIAVQLLTKDA	-10.3742	-10.486
HLA-A24:02	5HGA	3645	IEHQIAVQLLTKDA	-7.36249	-8.40559
HLA-A24:02	5HGA	3645	IEHQIAVQLLTKDA	-7.07591	-7.18771
HLA-B27:05	6PYJ	3645	IEHQIAVQLLTKDA	-8.75018	-8.86198
HLA-B44:05	3DX8	3645	IEHQIAVQLLTKDA	-5.28726	-5.39906
HLA-B44:05	3DX8	3645	IEHQIAVQLLTKDA	-4.30205	-5.34515
HLA-A02:01	6TDR	3645	IEHQIAVQLLTKDA	-4.2167	-4.3285

Top

Vaccine Design for the FusionNeoAntigens of TCF7L2-GRK5

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
TCF7L2-GRK5	chr10	114724383	chr10	121207635	4	15	KTIEHQIAVQL	ACGATTGAACACCAGATTGCAGTTCAGCTGCTC
TCF7L2-GRK5	chr10	114724383	chr10	121207635	5	15	TIEHQIAVQL	ATTGAACACCAGATTGCAGTTCAGCTGCTC
TCF7L2-GRK5	chr10	114724383	chr10	121207635	5	16	TIEHQIAVQLL	ATTGAACACCAGATTGCAGTTCAGCTGCTCACG
TCF7L2-GRK5	chr10	114724383	chr10	121207635	6	15	IEHQIAVQL	GAACACCAGATTGCAGTTCAGCTGCTC
TCF7L2-GRK5	chr10	114724383	chr10	121207635	6	16	IEHQIAVQLL	GAACACCAGATTGCAGTTCAGCTGCTCACG
TCF7L2-GRK5	chr10	114724383	chr10	121207635	7	15	EHQIAVQL	CACCAGATTGCAGTTCAGCTGCTC
TCF7L2-GRK5	chr10	114724383	chr10	121207635	7	16	EHQIAVQLL	CACCAGATTGCAGTTCAGCTGCTCACG
TCF7L2-GRK5	chr10	114724383	chr10	121207635	8	16	HQIAVQLL	CAGATTGCAGTTCAGCTGCTCACG
TCF7L2-GRK5	chr10	114724383	chr10	121207635	8	17	HQIAVQLLT	CAGATTGCAGTTCAGCTGCTCACGAAA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
TCF7L2-GRK5	chr10	114724383	chr10	121207635	10	25	IAVQLLTKDAKQRLG	GCAGTTCAGCTGCTCACGAAAGATGCGAAGCAGAGGCTGGGCTGC
TCF7L2-GRK5	chr10	114724383	chr10	121207635	11	26	AVQLLTKDAKQRLGC	GTTCAGCTGCTCACGAAAGATGCGAAGCAGAGGCTGGGCTGCCAG
TCF7L2-GRK5	chr10	114724383	chr10	121207635	3	18	YKTIEHQIAVQLLTK	AAAACGATTGAACACCAGATTGCAGTTCAGCTGCTCACGAAAGAT
TCF7L2-GRK5	chr10	114724383	chr10	121207635	6	21	IEHQIAVQLLTKDAK	GAACACCAGATTGCAGTTCAGCTGCTCACGAAAGATGCGAAGCAG
TCF7L2-GRK5	chr10	114724383	chr10	121207635	7	22	EHQIAVQLLTKDAKQ	CACCAGATTGCAGTTCAGCTGCTCACGAAAGATGCGAAGCAGAGG

Top

Information of the samples that have these potential fusion neoantigens of TCF7L2-GRK5

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
COAD	TCF7L2-GRK5	chr10	114724383	ENST00000349937	chr10	121207635	ENST00000369108	TCGA-AA-3837-01A

Top

Potential target of CAR-T therapy development for TCF7L2-GRK5

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to TCF7L2-GRK5

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to TCF7L2-GRK5

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Hgene	TCF7L2	C0036341	Schizophrenia	4	PSYGENET
Hgene	TCF7L2	C0011860	Diabetes Mellitus, Non-Insulin-Dependent	3	CTD_human
Hgene	TCF7L2	C0009402	Colorectal Carcinoma	2	CTD_human;UNIPROT
Hgene	TCF7L2	C0009404	Colorectal Neoplasms	2	CTD_human
Hgene	TCF7L2	C0001418	Adenocarcinoma	1	CTD_human
Hgene	TCF7L2	C0005586	Bipolar Disorder	1	PSYGENET
Hgene	TCF7L2	C0007102	Malignant tumor of colon	1	CTD_human
Hgene	TCF7L2	C0007193	Cardiomyopathy, Dilated	1	CTD_human
Hgene	TCF7L2	C0009375	Colonic Neoplasms	1	CTD_human
Hgene	TCF7L2	C0010068	Coronary heart disease	1	CTD_human
Hgene	TCF7L2	C0020507	Hyperplasia	1	CTD_human
Hgene	TCF7L2	C0036337	Schizoaffective Disorder	1	PSYGENET
Hgene	TCF7L2	C0087031	Juvenile-Onset Still Disease	1	CTD_human
Hgene	TCF7L2	C0151744	Myocardial Ischemia	1	CTD_human
Hgene	TCF7L2	C0205641	Adenocarcinoma, Basal Cell	1	CTD_human
Hgene	TCF7L2	C0205642	Adenocarcinoma, Oxyphilic	1	CTD_human
Hgene	TCF7L2	C0205643	Carcinoma, Cribriform	1	CTD_human
Hgene	TCF7L2	C0205644	Carcinoma, Granular Cell	1	CTD_human
Hgene	TCF7L2	C0205645	Adenocarcinoma, Tubular	1	CTD_human
Hgene	TCF7L2	C0600519	Ventricular Remodeling	1	CTD_human
Hgene	TCF7L2	C0600520	Left Ventricle Remodeling	1	CTD_human
Hgene	TCF7L2	C1449563	Cardiomyopathy, Familial Idiopathic	1	CTD_human
Hgene	TCF7L2	C1535926	Neurodevelopmental Disorders	1	CTD_human
Hgene	TCF7L2	C2931456	Prostate cancer, familial	1	CTD_human
Hgene	TCF7L2	C3495559	Juvenile arthritis	1	CTD_human
Hgene	TCF7L2	C3714758	Juvenile psoriatic arthritis	1	CTD_human
Hgene	TCF7L2	C4552091	Polyarthritis, Juvenile, Rheumatoid Factor Negative	1	CTD_human
Hgene	TCF7L2	C4704862	Polyarthritis, Juvenile, Rheumatoid Factor Positive	1	CTD_human
Hgene	TCF7L2	C4722327	PROSTATE CANCER, HEREDITARY, 1	1	CTD_human

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)